Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000173216 | Prostate | BPH | formation of cytoplasmic translation initiation complex | 14/3107 | 16/18723 | 1.01e-09 | 4.58e-08 | 14 |
GO:002241117 | Prostate | BPH | cellular component disassembly | 121/3107 | 443/18723 | 6.34e-09 | 2.25e-07 | 121 |
GO:007233217 | Prostate | BPH | intrinsic apoptotic signaling pathway by p53 class mediator | 34/3107 | 76/18723 | 8.04e-09 | 2.77e-07 | 34 |
GO:190179618 | Prostate | BPH | regulation of signal transduction by p53 class mediator | 38/3107 | 93/18723 | 2.31e-08 | 6.99e-07 | 38 |
GO:000640316 | Prostate | BPH | RNA localization | 65/3107 | 201/18723 | 2.76e-08 | 8.13e-07 | 65 |
GO:190179818 | Prostate | BPH | positive regulation of signal transduction by p53 class mediator | 16/3107 | 25/18723 | 1.43e-07 | 3.36e-06 | 16 |
GO:000961510 | Prostate | BPH | response to virus | 99/3107 | 367/18723 | 2.82e-07 | 6.07e-06 | 99 |
GO:20012448 | Prostate | BPH | positive regulation of intrinsic apoptotic signaling pathway | 25/3107 | 58/18723 | 1.76e-06 | 2.94e-05 | 25 |
GO:00329849 | Prostate | BPH | protein-containing complex disassembly | 65/3107 | 224/18723 | 2.19e-06 | 3.60e-05 | 65 |
GO:00430879 | Prostate | BPH | regulation of GTPase activity | 88/3107 | 348/18723 | 2.04e-05 | 2.49e-04 | 88 |
GO:003461216 | Prostate | BPH | response to tumor necrosis factor | 68/3107 | 253/18723 | 2.22e-05 | 2.67e-04 | 68 |
GO:005123610 | Prostate | BPH | establishment of RNA localization | 49/3107 | 166/18723 | 2.26e-05 | 2.71e-04 | 49 |
GO:005065710 | Prostate | BPH | nucleic acid transport | 48/3107 | 163/18723 | 2.92e-05 | 3.34e-04 | 48 |
GO:005065810 | Prostate | BPH | RNA transport | 48/3107 | 163/18723 | 2.92e-05 | 3.34e-04 | 48 |
GO:190225310 | Prostate | BPH | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 14/3107 | 29/18723 | 7.48e-05 | 7.24e-04 | 14 |
GO:007135616 | Prostate | BPH | cellular response to tumor necrosis factor | 60/3107 | 229/18723 | 1.42e-04 | 1.26e-03 | 60 |
GO:000641410 | Prostate | BPH | translational elongation | 20/3107 | 55/18723 | 3.18e-04 | 2.43e-03 | 20 |
GO:00017317 | Prostate | BPH | formation of translation preinitiation complex | 7/3107 | 11/18723 | 6.10e-04 | 4.16e-03 | 7 |
GO:001593110 | Prostate | BPH | nucleobase-containing compound transport | 55/3107 | 222/18723 | 1.12e-03 | 6.97e-03 | 55 |
GO:00435478 | Prostate | BPH | positive regulation of GTPase activity | 61/3107 | 255/18723 | 1.58e-03 | 9.23e-03 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EIF5 | SNV | Missense_Mutation | | c.39C>G | p.Phe13Leu | p.F13L | P55010 | protein_coding | deleterious(0.03) | possibly_damaging(0.558) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
EIF5 | SNV | Missense_Mutation | | c.238C>T | p.His80Tyr | p.H80Y | P55010 | protein_coding | deleterious(0) | benign(0.277) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
EIF5 | SNV | Missense_Mutation | rs779336285 | c.124G>A | p.Val42Ile | p.V42I | P55010 | protein_coding | tolerated(0.55) | benign(0.013) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EIF5 | SNV | Missense_Mutation | | c.33N>G | p.Asp11Glu | p.D11E | P55010 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-E2-A14O-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
EIF5 | insertion | In_Frame_Ins | novel | c.321_322insTGTCTTGCAGCTTATTCGCCTCAT | p.Thr107_Asp108insCysLeuAlaAlaTyrSerProHis | p.T107_D108insCLAAYSPH | P55010 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
EIF5 | insertion | Nonsense_Mutation | novel | c.507_508insCGAGGTCAGGAGTTCTAGACCAGCCTAGCCAACAT | p.Asn170ArgfsTer6 | p.N170Rfs*6 | P55010 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EIF5 | insertion | Nonsense_Mutation | novel | c.311_312insCGTCTGATTGCCAAGGTAATAAACTGCTCTTCAATTTAGT | p.Pro105ValfsTer2 | p.P105Vfs*2 | P55010 | protein_coding | | | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
EIF5 | SNV | Missense_Mutation | novel | c.1204N>A | p.Glu402Lys | p.E402K | P55010 | protein_coding | deleterious(0.02) | benign(0.173) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
EIF5 | SNV | Missense_Mutation | novel | c.89N>G | p.Asn30Ser | p.N30S | P55010 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
EIF5 | SNV | Missense_Mutation | novel | c.173N>T | p.Gly58Val | p.G58V | P55010 | protein_coding | deleterious(0) | benign(0.267) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |